Enhertu top seller among five solid tumor ADCs

Enhertu’s launch trajectory showed no signs of slowing last year, with its nearly $3 billion in annual sales representing an 80% increase over 2022. That growth propelled the product into the position of top seller among five antibody-drug conjugates approved for solid tumors, surpassing fellow HER2 ADC Kadcyla. 

Kadcyla, which is marketed by  Roche (SIX:ROG; OTCQX:RHHBY), had a six-year head start on Enhertu, to which AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) share rights. Kadcyla, also known as ado-trastuzumab emtansine, was first approved in 2013 for HER2-positive metastatic breast cancer, while Enhertu, also known as fam-trastuzumab deruxtecan, was approved in a similar setting in 2019. ...